HIGHLIGHTS Data from preclinical studies in ovarian cancer presented at premier international conference in Boston, USA. Results indicate that Amplia’s proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models of chemotherapy-resistant high-grade…